AffiliationBreast Cancer Family History Clinic, Nightingale Center, Withington Hospital, South Manchester University Hospital Trust, Manchester, UK. firstname.lastname@example.org
MetadataShow full item record
AbstractThe impact of chemoprevention trials can be hampered by poor participant compliance with the study medication. We used medication monitoring systems and pill count data to try to establish factors that may predict compliance with the International Breast Intervention Study (IBIS) and whether the participants went on to complete or benefit the trial. Women who took their trial medication in a regular pattern rather than randomly were more likely to be of benefit to the study (p = 0.003). For those women who failed to complete the study, compliance was shown to gradually reduce at each follow-up appointment. The taking of additional prescribed medication and not smoking were important factors in predicting completion (p = 0.04 and p = 0.047, respectively) and benefit (p = 0.037 and p = 0.031, respectively) to the study. Taking these factors into account when advising women at the start of a chemoprevention trial may be helpful in improving compliance.
CitationPredicting compliance in a breast cancer prevention trial., 12 (5):446-50 Breast J
JournalThe Breast Journal
- Breast cancer risk assessment in a mammography screening program and participation in the IBIS-II chemoprevention trial.
- Authors: Loehberg CR, Jud SM, Haeberle L, Heusinger K, Dilbat G, Hein A, Rauh C, Dall P, Rix N, Heinrich S, Buchholz S, Lex B, Reichler B, Adamietz B, Schulz-Wendtland R, Beckmann MW, Fasching PA
- Issue date: 2010 May
- How to decrease the non-compliance in a clinical trial.
- Authors: Baratelli GM, Allio W, Lanzani A, Valsecchi P, Rotmensz N
- Issue date: 2002 Feb
- Tamoxifen for breast cancer chemoprevention: low uptake by high-risk women after evaluation of a breast lump.
- Authors: Taylor R, Taguchi K
- Issue date: 2005 May-Jun
- Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy.
- Authors: Veronesi U, Maisonneuve P, Rotmensz N, Bonanni B, Boyle P, Viale G, Costa A, Sacchini V, Travaglini R, D'Aiuto G, Oliviero P, Lovison F, Gucciardo G, del Turco MR, Muraca MG, Pizzichetta MA, Conforti S, Decensi A, Italian Tamoxifen Study Group.
- Issue date: 2007 May 2
- Validation of a model predicting enrollment status in a chemoprevention trial for breast cancer.
- Authors: Yeomans Kinney A, Vernon SW, Shui W, Weber DV, Schell M, Vogel VG
- Issue date: 1998 Jul